Abstract. Thrombospondin (TSP), a major plateletsecreted protein, has recently been shown to have activity in tumor cell metastasis, cell adhesion, and platelet aggregation. The type 1 repeats of TSP contain two copies of CSVTCG and one copy of CSTSCG, per each of the three polypeptide chains of TSP and show homology with peptide sequences found in a number of other proteins including properdin, malarial circumsporozoite, and a blood-stage antigen of Plasmodium falciparum . To investigate whether these common sequences functioned as a cell adhesive domain in TSP, we assessed the effect of peptides corresponding to these sequences and an antibody raised against one of these sequences, CSTSCG, in three biological assays which depend, in part, on the cell adhesive activity of TSP These assays were TSP-dependent cell adhesion, T HROMBOSPONDIN (TSP)l is a 450,000-dalton glycoprotein secreted by platelets in response to such physiological activators as thrombin and collagen (9). TSP comprises 3% of the total platelet protein and 25% of the total platelet-secreted protein (26) . Although the precise biological role of TSP has yet to be fully established, it is generally accepted that TSP plays a major role in cell adhesion and cell-cell interactions . For example, TSP was found to promote the cell-substratum adhesion of a variety ofcells, including platelets, melanoma cells, muscle cells, endothelial cells, fibroblasts, and epithelial cells (24) . In addition, cells with very specialized functions such as keratinocytes (27) and osteoblasts (16) attach to TSP. Finally, TSP promotes the irreversible aggregation of platelets (23) .
Abstract. Thrombospondin (TSP), a major plateletsecreted protein, has recently been shown to have activity in tumor cell metastasis, cell adhesion, and platelet aggregation. The type 1 repeats of TSP contain two copies of CSVTCG and one copy of CSTSCG, per each of the three polypeptide chains of TSP and show homology with peptide sequences found in a number of other proteins including properdin, malarial circumsporozoite, and a blood-stage antigen of Plasmodium falciparum . To investigate whether these common sequences functioned as a cell adhesive domain in TSP, we assessed the effect of peptides corresponding to these sequences and an antibody raised against one of these sequences, CSTSCG, in three biological assays which depend, in part, on the cell adhesive activity of TSP These assays were TSP-dependent cell adhesion, T HROMBOSPONDIN (TSP)l is a 450,000-dalton glycoprotein secreted by platelets in response to such physiological activators as thrombin and collagen (9) . TSP comprises 3% of the total platelet protein and 25% of the total platelet-secreted protein (26) . Although the precise biological role of TSP has yet to be fully established, it is generally accepted that TSP plays a major role in cell adhesion and cell-cell interactions . For example, TSP was found to promote the cell-substratum adhesion of a variety ofcells, including platelets, melanoma cells, muscle cells, endothelial cells, fibroblasts, and epithelial cells (24) . In addition, cells with very specialized functions such as keratinocytes (27) and osteoblasts (16) attach to TSP. Finally, TSP promotes the irreversible aggregation of platelets (23) .
Thrombospondin has been postulated to play a role in malarial infection induced by only one strain of malaria, Plasmodiumfalciparum, and tumor cell metastasis induced by small cell carcinoma and mouse sarcoma. During malarial infection, TSP promotes adhesion of parasitized red cells to endothelial cells (15) and during tumor cell metastasis 1 . Abbreviations used in this paper: KLH, keyhole limpet hemocyanin ; PRP, platelet-rich plasma ; TSP, thrombospondin .
® The Rockefeller University Press, 0021-9525/92/01/209/9 $2 .00 TheJournal of Cell Biology, Volume 116, Number 1, January 1992 209-217 platelet aggregation, and tumor cell metastasis. We found that a number of peptides homologous to CSV TCG promoted the adhesion of a variety of cells including mouse B16-F10 melanoma cells, inhibited platelet aggregation and tumor cell metastasis, whereas control peptides had no effect . Anti-CSTSCG, which specifically recognized TSP, inhibited TSP-dependent cell adhesion, platelet aggregation, and tumor cell metastasis, whereas control IgG had no effect. These results suggest that CSVTCG and CSTSCG present in the type I repeats function in the adhesive interactions of TSP that mediate cell adhesion, platelet aggregation, and tumor cell metastasis. Peptides, based on the structure of these repeats, may find wide application in the treatment of thrombosis and in the prevention of cancer spread .
TSP promotes adhesion of mouse sarcoma cells to the vascular bed (20) and expression of the malignant phenotype of small cell carcinoma (3). Furthermore, TSP has been shown to share sequence homologies with malarial circumsporozoite proteins (8) , which function in the cellular adhesion of the sporozoite stage of the malarial parasite . Recently, Robson et al . (17) further noted that the most significant homology is based around the consensus sequence WSPCSVTCG, which is present inthree homologous copies in TSP (referred to as the type 1 repeats; 11), six copies in properdin and one copy each in all of the malarial circumsporozoite proteins studied to date including the blood-stage antigen of P. falciparum. Based on the evidence described above, we postulated that the sequences contained in the type 1 repeats of TSP must be playing a very fundamental role in ligand-receptor interactions mediating cellular adhesion . Therefore to test this hypothesis, the cell adhesive activities ofsynthetic peptides corresponding to these sequences were evaluated for activity in TSP-dependent cell-substratum adhesion assays and in the biological processes of platelet aggregation andtumor cell metastasis, which inpartdepend on the adhesive activities of TSP. In the present study we demonstrate that these sequences mediate TSP-dependent adhesive inter-actions and play a role in platelet aggregation and tumor cell metastasis. Our results confirm the recent studies of Rich et al . (14) and Prater et al . (13) who showed that sequences containing VTCG can function as cell recognition sites.
Materials and Methods

Materials
All reagents, unless specified otherwise, were purchased from Sigma Chemical Co. (St . Louis, MO) . Tissue culture supplies were purchased from ICN Flow (Irvine, CA) .
CellAdhesion Assay
The cell adhesion assay was performed as previously described (22) . Briefly, 2 jig of each peptide or TSP in 50 id Hepes-buffered saline, pH 7.35 was dried under nitrogen in the wells of microtiter plates . 100 pl of a suspension containing 2 x 103 cells/ml in Hepes-buffered saline, pH 7.35, containing 100 pM MnC12 , and 5 mM glucose was incubated in the peptidecoated well for 30-60 min, non-adherent cells removed by aspiration, wells washed and total adherent cells determined by protein assay. Cells adhering to BSA-coated wells were 2-5 % of TSRadherent cells and considered background .
Direct Enzyme-linked Immunoadsorbent Assay ELISA assays were performed as previously described (25) . Briefly, microtiter plates were coated with 2 pg of TSP or 2 wg peptide and blocked with 1 % BSA for 1 h . Wells were incubated for 1 h with 50 pl of various dilutions of the first antibody in 10 mM phosphate buffer, pH 7.4, containing 150 mM NaCl, and 0.05% Tween-20 (PBST) . Wells were then washed three times in PBST and incubated for 1 h with 50 Al of a 1:800 dilution in PBST of alkaline phosphatase coupled rabbit anti-goat 4G. Wells were washed three times with PBST followed with three washes of PBST buffer containing no Tween-20 and treated with 50 pl of alkaline phosphatase substrate solution (1 mg/ml of p-nitrophenylphosphate in 0.10 M glycine, pH 10.4, containing 1 mM ZnC12 and 1 MM MgC12). After 30 min, color development was stopped by the addition of 5 Al of 1 N NaOH and absorbances determined at 405 run .
Peptide Antibody CSTSCG was coupled to maleimide activated keyhole limpet hemocyanin (KLH) according to the instructions provided with the Pierce Imject Activated Immunogen Conjugation Kit (Pierce Chemical Co., Rockford, IL) . Approximately 4 mg of peptide was coupled to 2 mg of KLH . A goat was injected subcutaneously with 1 mg of peptide-protein conjugate suspended in complete Freund's and boosted with two additional injections of 500 jig of peptide-protein conjugate in incomplete Freund's adjuvant three and five weeks after the first injection . Goat immunization and collection of serum was accomplished commercially through Hazelton Research Products, Inc. (Denver, PA) .
Polyclonal anti-CSTSCG was affinity purified on Sepharose-KLH, followed by Sepharose-TSP Briefly, IgG prepared by ammonium sulfate precipitation of 100 ml of anti-sera was dissolved in 50 nil of Hepesbuffered saline, pH 7.35 (column buffer), and passed over a 5 ml column of Sepharose containing 15 mg of coupled KLH which was previously equilibrated with column buffer. The flow-through fraction was passed over a 1 ml column of Sepharose containing 2 mg of coupled TSP . The TSP column was then washed with 10 ml of column buffer and eluted with 0.1 M sodium citrate buffer, pH 2 .7. 1-ml fractions were collected in tubes containing 50 Al of 1 M Tris base to neutralize the final solution . Protein fractions were pooled, concentrated, and assessed for anti-TSP activity by ELISA and Western immunoblot analysis .
Platelet Aggregation
Platelet aggregation was performed as previously described (23) . Briefly, blood obtained from healthy volunteers was centrifuged to obtain plateletrich plasma (PRP) . The stirred PRP was aggregated with ADP in the presence and absence of peptide and the extent of aggregation monitored with a Chrono-log Aggregometer by measuring the increase in light transmission
The Journal of Cell Biology, Volume 116, 1992 as a function of time . Collagen-induced platelet aggregation was performed on washed human platelets isolated as previously described (21) . Briefly, platelets preincubated for 1 min with peptide were stirred with collagen at a final concentration of 5 pg/ml and the aggregation monitored optically with an aggregometer.
Synthetic Peptides
Synthetic peptides were purchased from Multiple Peptide Systems, (San Diego, CA) . The peptides were >95 % pure as assessed by HPLC and stored under argon at -20*C to prevent oxidation . Solutions were prepared immediately before use . For cell adhesion experiments, 2 kg of peptide was adsorbed on the surface of microtiter wells by drying under nitrogen 50 kl of a 40 pg/ml solution of peptide dissolved in Hepes-buffered salii.e. pH 7.35. In all other experiments, peptide stock solutions were 5-10 mg/ml iii Hepes-buffered saline, pH 7.35. The free thiol content of the peptide solutions was routinely checked spectrophotometrically by titration w ;*', Ellman's reagent (Pierce Chemical Co ., Rockford, IL) . Peptides containing free thiols were >90% in the reduced form . Peptides used for metastasis assays were endotoxin free as assessed by enzyme-linked immunoassay and were found non-toxic to cells during 24 h of culture.
TSP Purification
TSP was purified from Ca +2 ionophore À231ß7-activated platelets as previously described (26 Tumor cell metastasis was performed as previously described (20) . Briefly, B16-F10 melanoma cells were cultured in DME containing 10% FCS. Cells were harvested in log phase with EDTA, washed, and suspended in Hepesbuffered saline . Each peptide was either coinjected with 1 x 105 B16-F10
Tuszynski et al . Biological Activities of TSP Type 1 Repeats mouse melanoma cells into a lateral tail vein of a C57BL/6 mouse or serially injected into separate lateral tail veins. In some experiments cells were injected first and then peptide . Animals were sacrificed 14 d later and lung tumor colonies were counted . Cell viability at the beginning and end of the metastasis experiments was >90% as measured by trypan blue exclusion .
Western Immunoblotting
Anti-CSTSCG antibody was characterized by Western immunoblotting using Pharmacia's Phast gel electrophoresis system . Approximately 100 ng of TSP was separated under reducing conditions on an 8-25 % polyacrylamide gradient SDS gel. Gels were either silver stained or the proteins were electrophoretically transferred onto nitrocellulose paper. The paper was then blocked with 1% BSA in PBS-T and treated with 5 pg/ml of affinity purified goat anti-CSTSCG for 1 h, washed with PBS-T, developed according to the instructions provided with the VECTASTAIN ABC immunoperoxidase system, Vector Laboratories (Burlingame, CA) .
Results
TSRdependent Cell Adhesion
We chose to study CSVTCG and its related analogues because this sequence was present in two identical copies in the thrombospondin molecule . In addition, a computer search revealed that sequences analogous to this hexapeptide sequence were present or encoded by the cDNA of a number of apparently unrelated proteins suggesting some common function perhaps in ligand recognition (Table I) . Furthermore, preliminary experiments showed that peptides derived from TSP sequences upstream of CSVTCG containing the sequence, WSP, had no activity in our adhesion assay (data not shown) . In TSP, CSVTCG, and the related sequence CSTSCG occur in the type 1 repeats present in region E of the molecule which contains domains that interact with collagen and fibronectin (5), important adhesive extracellular matrix molecules ( Fig . 1) . Peptide CSVTCG and its analogues promoted 
the attachment of a variety of cells including both normal and tumor cells (Table 1I) . For example, B16-F10 mouse melanoma cells, A549 human lung adenocarcinoma cells, rabbit smooth muscle cells, and bovine aortic endothelial cells attached to the thrombospondin sequence CSVTCG 29-49 % compared to TSP. In contrast, the control peptides, TCVCGS, VCTGSC, and ANKHYF, displayed little or no significant cell adhesive activity. In addition, derivatives of CSVTCG, cyclic CSVTCG, in which the two cysteine residues are joined by disulfide residues to form a five-membered ring structure, and C(Acm)SVTC(Àcm), in which C(Acm) is an acetamidomethyl-blocked cysteine residue, promoted attachment of the four cell lines approximately to the same extent as CSVTCG . The substitution of R for G to yield CSVTCR displayed the greatest cell attachment activity of 90-159 % as compared to TSP. The peptide CSTSCR obtained by substituting R for G in CSTSCG, a sequence present in the type 1 repeats of TSP, also displayed a high adhesive activity of 39-104 % as compared to TSP. The human cancer cell line A549 adhered to this peptide to the same extent as TSP In addition, the morphological appearance of B16-F10 melanoma cells on CSVTCR resembled that observed on fibronectin, displaying a flattened morphology with numerous pseudopodia (Fig . 2) . Similar morphological changes on CSVTCR were observed for the other cells listed in Table H . It is possible that substitution of arginine for glycine or serine could increase the capacity of these peptides to bind cell associated glycosaminoglycans and thereby increase their adhesive activity. In support of this hypothesis is the observation that CRVTCG possessed heparin binding activity whereas CSVTCG did not (data not shown) .
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Platelet Aggregation
Peptide CSVTCG and its analogues inhibited ADP induced platelet aggregation (Fig . 3) . In contrast, the control peptides, ANKHYF and VCTGSC, displayed no activity. The active peptides specifically inhibited the formation of the ADP-induced second wave of platelet aggregation as indicated by the decreased extent of light transmission observed during the later stages of platelet aggregation shown in Fig.  3 . The lower extent of light transmission observed at later times during aggregation in the presence of active peptides was due to the formation of smaller platelet clumps (Fig. 4) . For example, Fig . 4 shows that in the absence of agonist no platelet clumps are formed, in the presence of agonist and buffer macroaggregates formed comprising more than 1,000 platelets per clump, while in the presence of agonist and CSVTCG only 10-50 platelets per clump were generated . The effect of peptides on aggregate size could not be attributed to an inhibition of platelet secretion since serotonin release was not affected (data not shown) . These peptides also inhibited platelet aggregation induced by collagen . For example, Table III (Table IV) . Peptides had no effect on the viability of B16-F10 cells in vitro. Cell growth in culture was not inhibited by peptides at concentrations as high as 1 mg/ml after 24 h and cells were >90% viable as measured by trypan blue exclusion (data not shown) . In addition, peptide solutions contained no endotoxin. To further rule out a direct effect of peptides on the metastatic potential of the cells, peptides were i.v. injected into one lateral tail vein followed by i.v. injection of tumor cells into the other lateral tail vein (Fig . 5) and the reverse i.e. tumor cells followed by peptide (Table IV) . In each case, inhibition of tumor cell metastasis of 39-75 % was observed . In contrast, the control peptides, ANKHYF and TCVCGS, had no significant effect on lung tumor colony formation, since the number of tumor colonies in the presence of these peptides 
Goat IgG
Anti-CSTSCG Immunoreactivity of anti-CSTSCG was measured by direct ELISA as described in Materials and Methods. Final antibody and IgG concentrations were 22 jug/ml. The average of three determinations is given t the standard deviation. Rat and mouse TSP was purified by the same procedure used to purify human TSP.
The oxidative state of the cysteine residues did not appear to influence the cell-substratum adhesive properties ofthe peptides examined in this study. For example, C(Acm)SVTC-(Acm)G, containing cysteine residues blocked with acetamidomethyl groups, which prevent inter-and intra-disulfide bond formation, and cyclic CSVTCG, which contains the two cysteine residues linked by disulfide bonds, both significantly promoted adhesion (Table II) . Similarly, C(Acm)-SVTC(Acm)G inhibited platelet aggregation (Fig. 3 ) and cyclic CSVTCG prevented tumor cell metastasis (Fig. 5 , Table  IV ) . The sequence CSVTCG probably exists in TSP with the cysteine residues disulfide-linked, since the three free thiol groups present in TSP can appear anywhere in positions 687-1149 (19) , while residues CSTSCG are contained in positions 373-378, and CSVTCG are contained in residues 429-434 and 486-491 of TSP Tb further establish that the type 1 repeats of TSP-promoted cell adhesive interactions, a polyclonal antibody to CSTSCG was prepared . The antibody was raised ina goatby immunizt= TV -FN
Control
Anfl-KLH Antl-CSTSCG Figure 7 . The effect of anti-CSTSCG on B16-F10 melanoma cell adhesion. Wells ofan eight-well glass tissue culture slide were coated with TSP and fibronectin as previously described (24) . Proteincoated surfaces were then treated with buffer or with 5 ul of a 500 j,g/ml solution ofeither affinity purified anti-CSTSCG or anti-KLH for 30 min and cell adhesion performed as described (24) . ing the animal with peptide coupled to KLH . The final antibody was adsorbed with KLH and affinity purified on a TSPSepharose column. The affinity purified antibody recognized the 180,000 dalton chain of TSP (Fig. 6 ). In addition, by means of direct immunoadsorbent assay, the antibody reacted with CSTSCG, CSVTCG, human TSP, rat TSP, mouse TSP, but not with BSA (Table V) . When adsorbed TSP was treated with this antibody and tested for cell adhesive activity, 70% of the cell adhesive activity of TSP was inhibited whereas the same antibody had no effect on fibronectinmediated adhesion (Fig. 7) . In addition, anti-KLH antibodies had no effect on TSP-mediated adhesion. Anti-CSTSCG at a concentration range of 33-70 pg/ml inhibited ADPinduced platelet aggregation and tumor cell metastasis by 73-80% (Fig. 8) . These results further support the conclusion that CSTSCG is a cell adhesive domain in TSP and provide strong evidence that peptides homologous to the type 1 repeats of TSP function in cell adhesive mechanisms .
Discussion
Our data suggest that the conserved sequences, CSVTCG and CSTSCG, present in the type 1 repeats of TSP function as adhesive domains that mediate the cell interactions involved in platelet aggregation and tumor cell metastasis. During the course ofthis work Rich and co-workers (14) published a study demonstrating that 18-20 amino acid peptides containing the sequence VTCG found in the malarial circumsporozoite protein and in the protein from the sexual stage ofP, falciparum promoted the attachment of a variety of human hematopoietic cell lines and two small cell carcinoma cell lines. Our studies are in agreement, since we find that peptides homologous to CSVTCG, which contain the VTCG sequence, promoted the attachment of a variety of cells including mouse melanoma cells and human lung adenocarcinoma cells . Shortly afterwards, Prater and co-workers (13) published a study showing that synthetic peptides corresponding to residues 424-42 and 481-99 of TSP promoted attachment of G361 cells but a peptide corresponding to residues 368-86 was inactive . The active peptides contained the sequence ASVTAG in place of CSVTCG and the inactive peptide contained the sequence ASTSAG in place of CSTSCG. The authors state that substitution of alanine for cysteine results in approximately a twofold loss in adhesive activity due to a lower coating efficiency of the alaninecontaining peptide. Another difference between the work of Prater et al . (13) andthe present study is that their mAb A4.1, the epitope for which localizes to the region of TSP containing the type 1 repeats, had no effect on platelet aggregation, 21 whereas our anti-CSTSCG antibody inhibited platelet aggregation . A possible explanation for this difference is that A4 .1 may not be directed against the same epitope as our antipeptide antibody. In our study, both CSTSCG and CSVTCG promoted cell adhesion suggesting that all three type 1 repeats per each of the three chains of TSP function as cell adhesive domains . The oxidative state ofthe cysteine groups did not appear to play a major role in the adhesion reaction since peptides having the cysteines blocked or oxidized promoted adhesion . For example, we found that peptide CSVTCG slowly oxidized in solution forming large intermolecular linked multimers that migrated with apparent molecular weights of 2,000 on SDS-gels . However, freshly prepared solutions were stable for at least 2 h. Our work further suggests that these sequences may play an important role in the adhesive interactions mediated by TSP in the process of platelet aggregation and tumor cell metastasis . For example, we show that ADP-induced platelet aggregation is inhibited by CSVTCG and its homologous peptides . The platelet aggregates formed in the presence of these peptides are small and reversible suggesting that these compounds do not effect platelet fibrinogen binding but rather TSP platelet binding which has been shown to promote the formation of large irreversible aggregates (23) . We think these peptides are inhibiting collagen-induced platelet aggregation by interfering with platelet collagen interaction . Further work is needed to clarify the mechanisms by which these peptides inhibit ADP and collagen-induced platelet aggregation .
We previously showed that TSP promoted the attachment of B16-F10 melanoma cells and that when intravenously in- 21 6 Figure 8. The effect of anti-CSTSCG on platelet aggregationand tumor cell metastasis. jected with tumor cells in syngeneic mice, TSP promoted the arrest of B16-F10 cells in the lung with a subsequent increase in the formation oflung tumor colonies as compared to controls (20) . In these early studies we postulated that endogenous TSP as well as exogenously added TSP promoted metastasis formation . The results of the present studies support the hypothesis that endogenous TSP mediates tumor cell metastasis in this model system . For example, the TSPpeptides, CSVTCG, and its homologous analogues, were found to inhibit metastasis by 39-85 % . More inhibition was found when peptides were coinjected with cells or injected before injection of cells than when cells were injected followed by peptide . One interpretation of these results is that the peptides, structurally similar or identical to the adhesive domain of mouse TSP, antagonize the cell adhesive activity of endogenous TSP which, in part, mediates the arrest oftumor cells in the lung. We propose that endogenous TSP promotes tumor cell metastasis by providing circulating tumor cells with a provisional extracellular matrix from which they can escape the circulation and invade the surrounding tissue . This is accomplished by platelets which secrete large quantities of TSP and promote its incorporation into a fibrin matrix. The TSP-rich fibrin matrix traps tumor cells in the microvasculature and enables them to adhere, retract the endothelium, and invade the surrounding stroma. We feel this mechanism has great relevance to human cancer since patients with active metastatic disease have high levels of circulating TSP (18) . In support of this interpretation for our model system are the recent studies of Lawler et al. (10) which indicate that the type 1 repeats in chicken, mouse, and human are highly conserved . For example, mouse TSP contains two CSVTCG sequences and one CTVTCG sequence whereas human TSP contains two CSVTCG sequences and one CSTSCG sequence. Therefore, it is likely that CSVTCG and related peptides could antagonize the adhesive activity of endogenous mouse TSP . To further establish that the sequences CSTSCG and CSVTCG functioned as TSP adhesive domains, a polyclonal antibody against CSTSCG was raised in a goat. The goat antibody was affinity purified on a TSP column, tested for reactivity against TSP by ELISA and Western immunoblot analysis and evaluated for activity in adhesion, aggregation, and metastasis assays. We found that anti-CSTSCG reacted with TSP, and blocked cell adhesion, platelet aggregation, and tumor cell metastasis. In the adhesion assay, even at the highest antibody doses tested, some cells still attached and spread on TSP suggesting that TSP must possess more than one cell adhesion domain. In platelet aggregation assays, the antibody inhibited only the second or secretion phase ofplatelet aggregation suggesting that platelet fibrinogen binding is not affected. Finally, the antibody significantly blocked tumor cell metastasis suggesting that the antibody interfered with the activity of endogenous mouse TSP . Since mouse TSP contains the related sequences, CTVTCG and CSVTCG (10), one might expect that anti-CSTSCG would bind mouse TSP and therefore block its activity. In fact, anti-CSTSCG antibody reacted with both mouse and rat TSP by direct ELISA supporting this proposed explanation for the antimetastatic activity of anti-CSTSCG.
In conclusion, these studies suggest that the conserved sequences homologous to CSVTCG in TSP and the malarial proteins may function in the binding of ligand receptor pairs that are fundamental in the cellular interactions governing malarial infection, hemostasis, and tumor cell metastasis. Elucidation of the receptors mediating these cellular events will provide more insight into the functional role of these conserved sequences .
